<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="995">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04348383</url>
  </required_header>
  <id_info>
    <org_study_id>IMIB-DFC-2020-02</org_study_id>
    <nct_id>NCT04348383</nct_id>
  </id_info>
  <brief_title>Defibrotide as Prevention and Treatment of Respiratory Distress and Cytokine Release Syndrome of Covid 19.</brief_title>
  <acronym>DEFACOVID</acronym>
  <official_title>Phase IIb Prospective, Multi-center, Randomized, Parallel, Double Blind, Placebo Controlled Trial to Evaluate Defibrotide Intravenous Infusion in the Prevention and Treatment of COVID-19 Respiratory Distress and Cytokine Release Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Protection of endothelial dysfunction by intravenous infusion of Defibrotide (Defitelio),
      expected to decrease inflammation and expression of adhesion molecules in the endothelium,
      leukocyte tissue infiltration and epithelial destruction, and to promote immune tolerance
      through a change in the Cytokine balance, which is decisive in preventing multiorgan failure
      and death in patients with SARS-CoV-2 infection with clinical status grade 4, 5 or 6
      according to the WHO classification
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Protection of endothelial dysfunction by intravenous infusion of Defibrotide (Defitelio),
      expected to decrease inflammation and expression of adhesion molecules in the endothelium,
      leukocyte tissue infiltration and epithelial destruction, and to promote immune tolerance
      through a change in the Cytokine balance, which is decisive in preventing multiorgan failure
      and death in patients with SARS-CoV-2 infection with clinical status grade 4, 5 or 6
      according to the WHO classification
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 8, 2020</start_date>
  <completion_date type="Anticipated">January 15, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 15, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Phase IIb prospective, multi-center, randomized, parallel, double blind, placebo controlled</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>double blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>1. Mortality rate</measure>
    <time_frame>: up to 30 days</time_frame>
    <description>All cause mortality</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical improvement by WHO</measure>
    <time_frame>7, 15, 30 and 60 Day</time_frame>
    <description>Decrease the rate of grades 4-5 patients requiring mechanical ventilation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical improvement by WHO</measure>
    <time_frame>7, 15, 30 and 60 Day</time_frame>
    <description>Decrease ventilation days in grade 6 patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical improvement by NEWS2 scales</measure>
    <time_frame>7, 15, 30 and 60 Day</time_frame>
    <description>Decrease the rate of grades 4-5 patients requiring mechanical ventilation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical improvement by NEWS2 scales</measure>
    <time_frame>7, 15, 30 and 60 Day</time_frame>
    <description>Decrease ventilation days in grade 6 patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biologic response</measure>
    <time_frame>7, 15, 30 and 60 Day</time_frame>
    <description>Decrease of IL-6 levels with respect to the basal ones &gt; 50%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biologic response</measure>
    <time_frame>7, 15, 30 and 60 Day</time_frame>
    <description>Absolute lymphocytes count: 50% increase with respect to the baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biologic response</measure>
    <time_frame>7, 15, 30 and 60 Day</time_frame>
    <description>Normal D-dimer (DD) or decrease of 50% with respect to the baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biologic response</measure>
    <time_frame>7, 15, 30 and 60 Day</time_frame>
    <description>Normal CRP or decrease of 50% with respect to the baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biologic response</measure>
    <time_frame>7, 15, 30 and 60 Day</time_frame>
    <description>Normal LDH or decrease of 50% with respect to the baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biologic response</measure>
    <time_frame>7, 15, 30 and 60 Day</time_frame>
    <description>Normal CPK or decrease of 50% with respect to the baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biologic response</measure>
    <time_frame>7, 15, 30 and 60 Day</time_frame>
    <description>Normal Ferritin or decrease of 50% with respect to the baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiological response</measure>
    <time_frame>7, 15, 30 and 60 Day</time_frame>
    <description>Improvement of radiological images by conventional radiology</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Collection and storage of biological samples</measure>
    <time_frame>15,30 days</time_frame>
    <description>improve the knowledge of the disease at the inclusion of the patients</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>COVID19</condition>
  <arm_group>
    <arm_group_label>Defibrotide + standard therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Defibrotide + standard therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo + standard therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Defibrotide 25 mg/kg 24 hours continuous infusion for 15 days</intervention_name>
    <description>Defibrotide 25 mg/kg 24 hours continuous infusion for 15 days</description>
    <arm_group_label>Defibrotide + standard therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo 250 cc 24 hours continuous infusion for 15 days</intervention_name>
    <description>Placebo 250 cc 24 hours continuous infusion for 15 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Acceptance of participation in the study by the patient or legal representative.

          2. Patients of any gender, 18 years or older.

          3. Confirmed diagnosis by PCR+ of SARS-CoV-2 infection.

          4. COVID-19 positive patients WHO grades 4, 5 or 6.

               -  Grade 4: hospitalized requiring oxygen therapy.

               -  Grade 5: hospitalized requiring high-flow oxygen therapy, noninvasive mechanical
                  ventilation, or both.

               -  Grade 6: hospitalized requiring ECMO, mechanical ventilation or both.Exclusion
                  Criteria:

          5. Levels of IL-6 ≥ 3 times the upper limit of normality

        Exclusion Criteria:

          1. Acute bleeding.

          2. Thrombolytic treatment and anticoagulant treatment at therapeutic doses.

          3. Pregnancy or lactation.

          4. Patients with active malignant tumour, other serious systemic or neuropsychiatric
             diseases.

          5. Patients participating in other clinical trials in the last month.

          6. Inability to give informed consent or to accomplish the requirements of the diagnostic
             tests.

          7. Patients with hypersensitivity to Defibrotide.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>José M. Moraleda, MD</last_name>
    <phone>+34 968369532</phone>
    <email>jmoraled@um.es</email>
  </overall_contact>
  <location>
    <facility>
      <name>Virgen de la Arrixaca University Clinical Hospital</name>
      <address>
        <city>Murcia</city>
        <zip>30120</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>April 8, 2020</study_first_submitted>
  <study_first_submitted_qc>April 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 16, 2020</study_first_posted>
  <last_update_submitted>August 12, 2020</last_update_submitted>
  <last_update_submitted_qc>August 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Defibrotide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

